Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines Therapeutics has filed a new drug application with the FDA for NGX267, the first of several compounds in the company's product pipeline that are designed to treat Alzheimer's disease.
Subscribe to our email newsletter
The compound NGX267 is a selective cholinergic muscarinic receptor agonist (M1 subtype) with properties suggesting the potential for both symptomatic and disease modification therapy in Alzheimer’s disease.
The M1 receptor plays an important role in memory and cognitive processing. Its activation has also been linked to decreases in two biochemical processes, AB production and tau protein phosphorylation, both of which are involved in the creation of the neurofibrillary tangles and amyloid plaques that are major histopathological hallmarks of Alzheimer’s disease.
“By selectively enhancing M1 cholinergic neurotransmission in the brain, NGX267 may offer advantages over current therapies for Alzheimer’s disease due to the relative preservation of this system in patients who are clinically symptomatic,” explains Dr Michael Murphy, senior vice president for discovery and development at TorreyPines.
NGX267 and a follow-on compound, NGX292, were licensed by TorreyPines, formerly called Neurogenetics, from Life Science Research Israel.